• Metadoro
  • Products
  • News and analysis

News and analysis

Check market insights shared by our community members
09.01.2025
VeChain Is Suffering on Rising Borrowing Costs

VeChain (VET) has fallen 12.7% this week, trading at $0.0445, underperforming the broader cryptocurrency market. Bitcoin (BTC), the leading cryptocurrency, has declined by 5.6% to $93,220, with bearish momentum building as it approaches key support at $89,000-$91,000. This decline is largely attributed to tightening monetary conditions in the United States, which continue to weigh on risk assets. Investor confidence is further shaken by significant net outflows from spot BTC-ETFs, which lost $583 million on Wednesday, marking the second-largest single-day outflow on record.

If BTC falls below the critical support level of $89,000-$91,000, VeChain is likely to extend its losses, with prices potentially declining another 10% to $0.0400. A sustained drop in BTC could push VET even lower, towards $0.0300. Conversely, a strong rebound in BTC prices to the $100,000 level could drive VET back up to $0.0500, representing a recovery of approximately 12% from current levels.

16.01.2025
Delta Is Taking Off To Update Its Highs

Delta Air Lines stock rose markedly by low double digits in the first ten days of the new year. The U.S. carrier has served more than 200 million customers in 2024, when it was also recognized by J.D. Power, a leading American data analytics and consumer intelligence company, for being No. 1 in First/Business and Premium Economy Passenger Satisfaction. Travelers became more willing to spend extra money for swanky seats when meeting a high level of service. Delta is just positioning itself as the nation's premium airline. And what's more important, its Christmas quarter's earnings reportedly surpassed average analyst pool projections. Driven by stronger travel demand, smart financial management and capacity discipline, Delta business provided last three-months' profit of $1.85 per share vs $1.28 at the same period one year ago, compared to $1.75 in consensus estimates. On January 10, the airline industry leader put its future profit levels within a range between $0.70 and $1 per share in the current quarter through the end of March, while analyst expectations were focused on $0.77 cents, according to data compiled by LSEG. The starting months of each year always perform worse. It is clear that all carriers made losses in the Covid years of 2020-2022, but Delta profits only recovered into a range from $0.25 to $0.45 in the first quarter of 2023 and 2024, respectively, but Q1 profit numbers varied from $0.75 to $0.96 even in the three blessed years before the pandemic. Delta added that it is forecasting annual earnings in excess of $7.35 a share, which would be the highest in its 100-year history, based on its planned revenue growth of 7% to 9% in the March quarter from a year ago. The announcement could be compared to an adjusted profit of $6.16 a share in 2024. The company happily breaks through ticket prices' rising effects, almost undisturbed by a reduction in airline seats in the domestic market, which was peculiar for most carriers. Thus, new expectations created a fertile ground for setting new price records, even though price movements on Delta charts look most convincing among its other American rivals.

By the way, Citigroup analysts freshly updated their outlook on Delta Air Lines shares to raise their price target to $80 from the previous $77, vs the actual range around $65 per share where the stock just came after a reasonable market correction from last week's and all-time highs. Citigroup said it has included factors like higher revenue per available seat mile, projections of slightly lower fuel prices, increased taxation, a minor rise in share count, and the incorporation of fourth-quarter 2024 results into their financial model, which has projected Delta's profit at $7.49 per share in 2024 and $8.72 in 2025. Delta shares are Buy-rated at Citi, and we agree with their positive estimates in general, while keeping in mind even better price goals somewhere between $82.5 and $85.

23.01.2025
Ontology Is Sliding Towards $0.2000

Ontology (ONT) is down 2.3% this week, trading at $0.2176, in line with the broader crypto market where Bitcoin (BTC) has declined 2.0% to $101,632. While the new U.S. administration has made some strides toward fairer crypto regulation, Donald Trump has remained silent on the highly anticipated issue of adding Bitcoin to U.S. federal reserves.

Market speculation is rampant, with figures like BlackRock CEO Larry Fink suggesting Bitcoin could surge to $700,000 per coin if sovereign wealth funds begin accumulating. Other forecasts predict Bitcoin reaching $250,000 by year-end. While such projections could foster optimism, the lack of decisive action or announcements regarding U.S. crypto reserves is weighing heavily on the market.

For Ontology, the situation remains bearish. Having breached the critical support at $0.2500 last week, the token is now approaching the $0.2000 level. A failure to provide clear evidence or statements about U.S. federal crypto reserve plans could see ONT fall even further, breaching the $0.2000 mark and deepening its losses.

14.01.2025
Tezos Is Seen Hodling above $1.200

Tezos (XTZ) has declined slightly by 0.2% this week, trading at $1.249, following Bitcoin’s (BTC) drop to $89,158, which triggered widespread altcoin sell-offs due to concerns of a potential further decline in BTC to $80,000. However, Bitcoin managed to hold above the critical support level at $89,000-$91,000, offering some relief to the broader crypto market.

Speculation about a shift in U.S. trade policy has provided additional support to crypto assets. Reports suggest the new U.S. administration may pursue a gradual increase in tariffs rather than an abrupt hike, which could help alleviate inflationary pressures and lead to a less aggressive monetary stance from the Federal Reserve.

This development is a positive signal for the cryptocurrency market and may help Tezos maintain its position above the key support level of $1.200.

14.01.2025
Merck Becomes Interesting to Be Added to a Portfolio

Merck & Co (MRK) stocks have shown signs of becoming a compelling buy opportunity. Over the past six months, the stock has been in a downtrend, declining 29.8% to $94.50 per share. However, since mid-November, MRK has demonstrated a reversal of momentum, rebounding by 10.0% to reach $104.87 on December 5. Following a brief pullback and consolidation period, the stock has retested the downtrend resistance and appears poised to continue its upward trajectory.

With prices currently positioned to target $110.00, this represents a potential 9-10% upside from the present levels. Setting a stop-loss at $93.50 aligns with a prudent risk management strategy, providing protection against further downside while allowing for upside potential. The recent consolidation phase further supports the case for a breakout, making this an attractive moment to consider initiating or adding to a position in MRK.

Microsoft May Go to December 2023 Dips

The Windows OS developer joined the widening group of tech companies that partially lost their market values this month. In almost every case, a price drop happened despite solid, and even better-than-expected quarterly numbers.

This all started with Google-parent Alphabet's decline last week, after only one conventionally weak spot has been discovered in its YouTube segment, while other parts of its business performed strongly, though didn't break any new records. In a very similar way, late yesterday evening Microsoft posted its earnings per share (EPS) of $2.95 on sales of $64.7 billion instead of EPS of $2.94 per share on sales of $64.38 billion in consensus estimates. Money-generation indications showed only an inch higher compared with the recent two quarters, despite 4.5% growth in revenue quarter-by-quarter and nearly 15% jump in quarterly revenue year-on-year. However, this is not enough reason for an immediate continuation of the price rally, so that Microsoft share price went down to test the levels well below $400, losing more than 6.5% already within the first hours of the extended trading on Wall Street.

A nominal excuse for Microsoft share price sinking was attributed to its Azure cloud business growth pace at 29% to slightly miss overheated average analyst pool bets on 30.2%, probably made out of the blue beforehand. Anyway, a slowdown is detected compared to 31% YoY at the end of the previous quarter. Now, searching for a new bottom in one of the three most capitalized companies in the world would become another challenge for the nervous market community during the hot corporate reports' season. A price discount against the fresh all-time high at $468.35 (set on July 5) reaches a large amount of about $75 per share, or 16%, when moving within current price ranges.

By the way, AI (artificial intelligence) related pace accounted for about 8% of Azure's numbers, up from 7% in Q1 to prove higher AI demand. Good for other giants' business on the AI basis, but no obstacle for some further price adjustment in both Microsoft stock and broader markets. Capital spending jumped to $19 billion from $14 billion in Q1 2024 and $10.7 billion in Q2 2023. Revenue in productivity and business processes rose 11% to $20.3 billion to lay the backbone for a more profitable future. However, the current price move may lead to a test of lower dips between $360 and $375, last seen in December 2023, according to our estimates. These technical levels may evoke a stronger buying activity.

3566
B
Buying More of Amazon

My personal feeling is that Amazon's quarterly report may have the ability to surprise investors from August 1st. During a recent background of massive correction moves in techs, shares of Amazon lost about 7.5% from 8th to 30th of July, compared to the e-commerce bellwether's peaking price above $200. This represented not such a big discount compared to many other components of the Nasdaq Composite index, pointing that the crowd wants to believe in Amazon's strength. Meanwhile, the impact of Microsoft's drop in the after-hours trading yesterday quickly increased this gap in Amazon price to 12% from all-time highs, which makes shares of Amazon much more attractive.

Analysts' consensus projections for a more than 10% surplus in Q2 sales to approach $150 billion are here, also betting for an EPS at least an inch above the psychological threshold of $1 per share, as it was last Christmas quarter's record achievement for the time being. However, could you imagine what would happen with a price if actual numbers come out far beyond consensus estimates? First, accelerating demand on cloud computing is a factor to drive Amazon Web Services (AWS) marginality up to the skies. The help of generative AI tailwinds is real. If so, forget about Amazon's core business, even though it is seemingly climbing to new highs as well. The retail platform and advertising income may benefit much from Amazon's faster deliveries, which may give more conversion, despite all those struggling low-end consumers. There was a big crowd of new loyalty program sign-ups on Prime Day. It generated $14 billion in sales in the US to mark nearly 11% of gains YoY, Adobe Analytics figured. This may boost overall record sales well above consensus ideas. I anticipate the sales number above $155 billion and EPS of $1.10 or even better.

That's why I decided to buy more Amazon shares, even without waiting for the official quarterly release. A break through $190 may give an extra boost to the stock's price immediately, but I don't want to buy above $200, when it currently trades between $175 and $180. Well, if something goes wrong, Amazon will come back soon. Yet, in my baseline scenario, the stock price would soar by double-digits, in after-hours this Thursday's night. Citigroup now has its target price for Amazon at $245 (!) per share, projecting a 17.5% surplus in AWS and operating income of $13.88 billion. This is surely not the main argument for my mind, but this certainly gives me extra power to stay positive on Amazon.

3160
A Chance to Add More to Stakes in Merck

Merck & Company quickly lost about 4% of its market value in the pre-market trading on July 30, to re-test its major $120 to $122.50 technical support area. This was an immediate response to the drug giant's updating its own earnings forecast for the rest of the year. Merck CEOs adjusted their guidance to a range between $7.94 and $8.04, from previous estimates of $8.53 to $8.65 per share. Yet, the main reasons for lower forecasts were seemingly boiling down to one-time charges from an acquisition of eye-focused drug developer EyeBio, which cost nearly $1.3 billion, or $0.51 per share. Consensus expectations at $8.16 per share included this factor into consideration, and so nothing extraordinary happened from our point of view.

Meanwhile, Merck business continued to win. Keytruda medicine for cancer immunotherapy, which used to make the largest revenue contribution, jumped above $30 billion annually, hitting $7.3 billion in the quarter, up 16% YoY vs expected numbers of slightly above $7.1 billion. Besides, Merck launched a drug Winrevair for a rare lung condition called pulmonary arterial hypertension. Many feel Winrevair may have a blockbuster potential, as it already gave $70 million in sales, which is higher than the most bullish estimates. Sales of Gardasil, a vaccine widely used in the prevention of human papillomavirus, were also growing. The company's boss Robert Davis separately emphasized Merck's participation in vaccine programs, including the US FDA regulatory approval and CDC's (The Centers for Disease Control and Prevention) recommendation for a pneumococcal vaccine, and positive results from a trial of an investigational RSV (respiratory syncytial virus) preventative monoclonal antibody for infants.

From a pure financial point of view, the company raised its full-year 2024 sales projections to a slightly higher range of $63.4 billion to $64.4 billion. Merck's sales globally rose by 7% to $16.1 billion, above average expectations of $15.8 billion, sales added 11% if the Wall Street crowd takes into account adjusting for currency exchange impacts. On Tuesday Merck also revealed $5.5 billion of Q2 profit, or $2.14 per share. Excluding this one-time stuff, the last quarter brought $2.28 per share vs consensus expectations of $2.15. The outlook looks so strong, that any current price discount is just an opportunity to add more to investors' stake in Merck. Merck is surely a top pick, even though not a buy for immediate use, better to postpone for a week or so until the dust settles.

2915
Rafael Quintana Martinez
Money Manager de alto rendimiento, con una sólida formación académica, profesional y de campo. Más de 9 años de experiencia especializada en el comercio de mercados financieros internacionales. La devoción, la fiabilidad, la responsabilidad y la ética impulsan mi vida. Actualmente me desempeño como Analista Senior para Metadoro. https://metadoro.com/es https://mx.investing.com/members/contributors/235587671/ https://es.tradingview.com/chart/EURUSD/rE9gVips/
APE Stuck in a Flat Range

ApeCoin (APE) is experiencing a rise of 4.7% this week, reaching $0.796. This increase has allowed the token to break through the resistance of the downside trend that has persisted since March 13. However, the current price movements are primarily within a flat range, indicating that APE is struggling to gain further upward momentum.

A potential catalyst for future growth is the ApeCoin DAO's proposal to create a Bored Ape-themed hotel in Bangkok, which is garnering significant support from the community. If the project proceeds, it could positively impact the token's value. With this development, APE has the potential to test the resistance level at $1.000.

3014
110

Join our community

Share your professional and amateur observations, exchange experiences, anticipate developments

Category
All
Stocks
Crypto
Etf
Commodities
Indices
Currencies
Energies
Metals
Instruments
Author
All
Metadoro
Contributors